Literature DB >> 9794366

CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice.

M J McCluskie1, H L Davis.   

Abstract

Mucosal immunity is difficult to induce with subunit vaccines unless such vaccines are administered with a mucosal adjuvant such as cholera toxin (CT); however, CT is toxic in humans. Synthetic oligodeoxynucleotides containing immunostimulatory CpG motifs (CpG) are potent adjuvants for the induction of Th1-like systemic immune responses against parenterally delivered proteins. Here, we show in mice that intranasal delivery of hepatitis B surface Ag, which alone has no effect, elicits good immune responses when given with CpG oligodeoxynucleotides and/or CT. Overall, CpG is superior to CT for the induction of humoral and cell-mediated systemic immunity as well as mucosal immune responses (IgA) at local (lung) and distant (feces) sites. Furthermore, CpG and CT act synergistically, giving stronger responses than those observed with 10 times more of either adjuvant alone. Ab isotypes were predominantly IgG1 (Th2-like) with CT, mixed IgG1/IgG2a (Th0) with CpG, and predominantly IgG2a (Th1-like) with CpG and CT together.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9794366

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  57 in total

1.  Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection.

Authors:  D M Klinman; J Conover; C Coban
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

Review 2.  The role of CpG in DNA vaccines.

Authors:  M J McCluskie; R D Weeratna; H L Davis
Journal:  Springer Semin Immunopathol       Date:  2000

3.  Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG-containing oligodeoxynucleotide and effective priming of influenza virus-specific CD4+ T cells.

Authors:  Anne-Sophie Beignon; Jean-Paul Briand; Sylviane Muller; Charalambos D Partidos
Journal:  Immunology       Date:  2002-02       Impact factor: 7.397

4.  Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus.

Authors:  Sang-Moo Kang; Richard W Compans
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

5.  Oral immunization with Porphyromonas gingivalis outer membrane protein and CpGoligodeoxynucleotides elicits T helper 1 and 2 cytokines for enhanced protective immunity.

Authors:  Chenlu Liu; Tomomi Hashizume; Tomoko Kurita-Ochiai; Kohtaro Fujihashi; Masafumi Yamamoto
Journal:  Mol Oral Microbiol       Date:  2010-06       Impact factor: 3.563

6.  Nasolacrimal duct closure modulates ocular mucosal and systemic CD4(+) T-cell responses induced following topical ocular or intranasal immunization.

Authors:  Aziz Alami Chentoufi; Gargi Dasgupta; Anthony B Nesburn; Ilham Bettahi; Nicholas R Binder; Zareen S Choudhury; Winston D Chamberlain; Steven L Wechsler; Lbachir BenMohamed
Journal:  Clin Vaccine Immunol       Date:  2010-01-20

Review 7.  Synthetic oligonucleotides as modulators of inflammation.

Authors:  Dennis Klinman; Hidekazu Shirota; Debra Tross; Takashi Sato; Sven Klaschik
Journal:  J Leukoc Biol       Date:  2008-04-22       Impact factor: 4.962

8.  Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen.

Authors:  Cevayir Coban; Ken J Ishii; Anthony W Stowers; David B Keister; Dennis M Klinman; Nirbhay Kumar
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

9.  Tweaking Innate Immunity: the Promise of Innate Immunologicals As Anti-infectives.

Authors:  Kenneth L Rosenthal
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-09       Impact factor: 2.471

10.  Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2.

Authors:  Qing He; Alaina Mitchell; Tulin Morcol; Steve J D Bell
Journal:  Clin Diagn Lab Immunol       Date:  2002-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.